ServisFirst Bancshares, Inc. announced a 33% increase in diluted earnings per share to $0.80 for Q3 2026 compared to the same period last year, driven by an 11% growth in loans and improved efficiency ratio of 30.20%. The bank maintained a stable net interest margin of 3.63% and increased book value per share by 14% year-over-year. Following a two-for-one stock split, the company also launched its first stock repurchase program. These results reflect solid economic trends and ongoing loan pipeline growth, positioning the bank for continued strong financial performance.
ServisFirst Bancshares, Inc. reported strong Q3 2026 earnings growth. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 142 priced US Financials stocks, 42 rose and 99 fell. Notable movers include GEMI at USD 3.23 with a -9.52% change and 56% sell activity, COIN at USD 172.94 down 5.91% with 82% buy activity, and UPST at USD 23.35 down 5.66%.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
